Systemic treatment for colorectal cancer

Slides:

Advertisements

Similar presentations

Advertisements

Mario Scartozzi Clinica di Oncologia Medica Ancona HIGHLIGHTS IN COLORECTAL CANCER MANAGEMENT TREATMENT OF METASTATIC DISEASE.

Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉財團法人台灣癌症臨床研究發展基金會.

T Staging: Rectal cancer T1 invades submucosa T2 invades muscularis propria T3 invades subserosa or perirectal tissues T4 invades peritoneum, organs or.

POSTGRADUATE SCHOOL OF MEDICINE DIARRHOEA

Aakash H. Gajjar, MD, FACS Assistant Professor of Surgery Colon & Rectal Surgery University of Texas Medical Branch Galveston, Texas February 10 th, 2014.

Case presentation Mr PR 58 year-old male. Initial Presentation Apr 2012 attending Golf Masters in America change in bowel habit was once daily, then increased.

PLWC Slide Deck Series: Understanding Colorectal Cancer Presents 2005.

Colorectal Cancer An oncologists perspective

Colon Cancer Treatment The Perspective of a Medical Oncologist

Individualizing Therapy for Gastrointestinal Malignancies 2010 Update

Statistics and Medicine – Friends or Foes? Monika Krzyzanowska MD MPH Medical Oncologist, Princess Margaret Cancer Centre Associate Professor of Medicine,

Colorectal Cancer Treatment Susan Rein, BSN RN CCRC.

Systemic Approach to Advanced Colon Cancer Mohamed Abdulla (M.D.) Ass. Prof. Clinical Oncology Kasr El-Aini School of Medicine Cairo University April,

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Upper gastrointestinal cancers

Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.

Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.

C. ENG 1, G. J. CHANG 2, P. DAS 3, M. RODRIGUEZ-BIGAS 2, J. M. SKIBBER 2, W. QIAO 4, G. L. ROSNER 4, L. T. UKEGBU 1, R. A. WOLFF 1, C.H. CRANE 3 DEPARTMENT.

Interventions for Clients with Colorectal Cancer

Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.

COLON CANCER A MAJOR ISSUE IN ALASKA. A common malignancy 200,000 cases in the U. S. in ,000 cases in the U. S. in 2008 Greater than 50 new cases.

Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.

Colon Rectum x1.85x2.35x1.87x2.48 1:111:8 1:11.

Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment.

The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena

Systemic Treatment of Metastatic Colorectal Cancer: Living with a Moving Landscape Neal J. Meropol, MD Fox Chase Cancer Center May 16, 2005.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Joseph A. De Soto M.D., Ph.D., F.A.I.C.

Clara Natoli, MD Professor of Medical Oncology University G. D ' Annunzio Chieti - Pescara Clara Natoli, MD Professor of Medical Oncology University G.

Dr Francis Daniel, MB. ChB, FFR-RCSI, FRCR. Consultant in Clinical Oncology

Prognosis of colon cancer compared with rectal cancer. Where lies the difference? Bjørn S. Nedrebø Stavanger University Hospital.

0 Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer NCCTG Intergroup Phase III Trial N0147 Jocelin Huang, Daniel J Sargent,

XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic.

Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.

Medical Management of Colorectal Cancer

Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first line advanced colorectal.

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

Cetuximab plus FOLFIRI 1 st -line in patients (pts) with metastatic colorectal cancer (mCRC): A quality of life (QoL) analysis of the CRYSTAL trial G.

LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.

Colorectal cancer Clinical case scenarios Mixed chemotherapy treatment options Educational Resource February 2012 Updated January 2015 NICE clinical guideline.

종양혈액내과 R4 고원진 / pf. 김시영 Rectal cancer : state of the art in 2012 Curr Opin Oncol 2012, 24:441–447.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Colon Cancer Stage I-III

CCO Independent Conference Highlights

CCO Independent Conference Coverage

Adjuvant therapy in colon cancer

Fig. 2. Atypical response to VEGF-targeted therapy in colon cancer

Systemic treatment for metastatic prostate cancer

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

PLWC Slide Deck Series: Understanding Colorectal Cancer

تهیه کننده: استاد مربوطه: بهار 1392

Colon Cancer Stages I-III

Fit for treatment Confirmed mCRC Request RAS Yes Liver only disease?

بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية

Mark W. Onaitis, MD, Rebecca P. Petersen, MD, John C

EORTC INTERGROUP : Perioperative FOLFOX4 for Potentially Resectable Colorectal Liver Metastases, Nordlinger,B et al June 4, 2007 Discussant Nicholas.

Patient-Centered Management in Pancreatic Cancer

Integration of EGFR targeting into first line therapy: is it time?

First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.

Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease,

Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing (MRC FOCUS)

Targeted Therapies for Hepatocellular Carcinoma

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.

Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.

Colorectal Cancer in Older Patients Key Issues

به نام او که زندگی از او رنگ می گیرد

Schema of the exploratory analyses (RAS wild-type population)

Presentation transcript:

Systemic treatment for colorectal cancer Ian Ingledew

Who gets what? Site of disease Stage Colon, rectum, anal cancer Stage Early disease (low risk – no chemo required) Early disease (high risk factors) Advanced/metastatic disease Resectable liver metastases?

Drugs Fluorouracil (5FU) Calcium Folinate (not chemo) Capecitabine Oxaliplatin Irinotecan Mitomycin Cetuximab (KRAS mutation)? Trifluridine/tipiracil (Lonsurf)

Common treatments OxMdG XELOX IrMdG +/- Cetuximab Chemoradiotherapy Capecitabine Infusional 5FU Mitomycin + 5FU (anal cancer)

Side effects Myelosuppression Diarrhoea Nausea/vomiting Capecitabine Irinotecan Nausea/vomiting Sensory peripheral neuropathy (temperature sensitive) Rash (cetuximab)

Cetuximab rash